Evercore ISI analyst Vijay Kumar lowered the firm’s price target on OraSure to $4.50 from $5.50 and keeps an In Line rating on the shares in an earnings preview for the MedTech, Life Science Tools and Diagnostics group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSUR:
- OraSure supports HIV testing initiatives for National HIV Testing Day
- OraSure Technologies Supports National HIV Testing Day
- Krystal Biotech, Virtu, StepStone, Cactus Inc., Tidewater to join S&P 600
- OraSure Technologies Stock Plan Expansion and Director Elections
- OraSure sees Q2 revenue $50M-$55M, consensus $53.73M